Alternatively spliced tissue factor and full-length tissue factor protect cardiomyocytes against TNF-α-induced apoptosis by Boltzen, U. et al.
Alternatively Spliced Tissue Factor and Full-length Tissue Factor
Protect Cardiomyocytes against TNF-α-induced Apoptosis
U Boltzena,†,*, A Eisenreicha,*, S Antoniak‡, A Weithaeusera,†, H Fechnera, W Pollera, HP
Schultheissa, N Mackman‡, and U Raucha
aCharité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Zentrum für Herz und
Kreislaufmedizin, D-12200 Berlin, Germany
†Freie Universität Berlin, Institute of Biochemistry, D-14195 Berlin, Germany
‡UNC McAllister Heart Institute, Division of Hematology and Oncology, Department of Medicine,
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Abstract
Tissue Factor (TF) is expressed in various cell types of the heart, such as cardiomyocytes. In
addition to its role in the initiation of blood coagulation, the TF:FVIIa complex protects cells from
apoptosis. There are two isoforms of Tissue Factor (TF): “full length” (fl)TF – an integral
membrane protein; and alternatively spliced (as)TF – a protein that lacks a transmembrane domain
and can thus be secreted in a soluble form. Whether asTF or flTF affect apoptosis of
cardiomyocytes is unknown.
In this study, we examined whether asTF or flTF protect murine cardiomyocytes from TNF-α-
induced apoptosis. We used murine cardiomyocytic HL-1 cells and primary murine embryonic
cardiomyocytes that overexpressed either murine asTF or murine flTF, and stimulated them with
TNF-α to initiate cell death. Apoptosis was assessed by Annexin-V assay, propidium iodide assay,
as well as activation of caspase-3 and -9. In addition, signaling via integrins, Akt, NFκB and
Erk1/2, and gene-expression of Bcl-2 family members were analyzed.
We here report that overexpression of asTF reduced phosphatidylserine exposure upon TNF-α-
stimulation. asTF overexpression led to an increased expression and phosphorylation of Akt, as
well as up-regulation of the anti-apoptotic protein Bcl-xL. The anti-apoptotic effects of asTF
overexpression were mediated via αVβ3/Akt/NFκB signaling and were dependent on Bcl-xL
expression in HL-1 cells. The anti-apoptotic activity of asTF was also observed using primary
cardiomyocytes. Analogous yet less pronounced anti-apoptotic sequelae were observed due to
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overexpression of flTF. Importantly, cardiomyocytes deficient in TF exhibited increased apoptosis
compared to wild type cells.
We propose that asTF and flTF protect cardiomyocytes against TNF-α-induced apoptosis via
activation of specific signaling pathways, and up-regulation of anti-apoptotic members of the
Bcl-2 protein family.
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1. Introduction
Tissue factor (TF) is the primary initiator of coagulation and is expressed in the heart in
various cell types, such as fibroblasts and cardiomyocytes [1–5]. Myocardial TF protects the
heart and other organs against hemorrhage [6]. TF is also located in intercalated discs in
cardiomyocytes. Moreover, it has been suggested that TF is involved in the maintenance of
the structural integrity of the myocardial muscle [7]. Pawlinski et al. showed that mice with
a selective deletion of the TF gene in cardiac myocytes exhibit increased hemosiderosis and
fibrosis after treatment with isoproterenol, indicating that TF plays a protective role under
pathological conditions [6].
In 2003, Bogdanov et al. described an alternatively spliced TF (asTF) isoform of TF [8].
Low levels of both asTF and flTF isoforms are present in blood [8–10]. The soluble asTF
isoform lacks the 5th exon, which results in a frame shift and the loss of the transmembrane
and cytosolic domains [8]. asTF has minimal pro-coagulant activity [8,11–15]. During heart
development, murine asTF and flTF exhibit similar expression patterns, but asTF is
maximally expressed at later stages [9]. flTF protects the heart against intra-cardiac
bleeding, although it was speculated that flTF has other roles in the heart tissue, including
maintenance of vessel stability [7]. Less is known about the biological function of asTF in
the heart. Our studies showed that both TF isoforms, flTF and asTF, were down-regulated in
the myocardium of patients with dilated cardiomyopathy [16].
asTF has been shown to have a pro-angiogenic effect in solid tumors [17]. In a recent study,
recombinant human asTF was demonstrated to induce angiogenesis non-proteolytically via a
mechanism that involves engagement of integrins αVβ3 and α6β1 on endothelial cells [13].
flTF also contributes to angiogenesis yet, unlike asTF, this effect is achieved via proteolytic
activation of protease-activated receptors (PARs) [18]. We note that flTF has been shown to
have both pro-apoptotic and anti-apototic activity, depending on the cell type (19,20,21). We
hypothesize that asTF may be an anti-apoptotic factor in the heart tissue.
Adult cardiomyocytes do not proliferate. Therefore, the loss of cardiomyocytes leads to
cardiac dysfunction. Protection of cardiomyocytes from apoptosis may ameliorate the
outcome of several life-threatening cardiac diseases. Myocardial hypoxia and inflammation
as well as hypertrophy are associated with an increased incidence of apoptosis [22–24].
Whether asTF and flTF modulate the survival of cardiomyocytes upon inflammatory
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stimulation is not known. Therefore, we sought to determine whether asTF or flTF has an
influence on the viability of cardiomyocytes.
2. Methods
2.1. Overexpression of asTF and flTF in HL-1 cells
HL-1 – murine cardiomyocytic cells [25] – were kindly provided by Prof. Claycomb
(Louisiana State University Health Sciences Center, New Orleans, LA, USA). HL-1 cells
were transfected with the murine asTF-plasmid or murine flTF-plasmid (containing the
complete coding sequence including the signaling peptide, beginning from the start codon
until the stop codon) using Lipofectamine2000 (Invitrogen) according to the manufacturer’s
instructions. As a control, HL-1 cells were transfected with an empty plasmid. For stable
transfection, the transfected cells were cultured in Claycomb medium [25] supplemented
with G418 (800 μg/mL, PAA) to select transfected cells for several passages. The mRNA
expression of the TF isoforms were measured by semi-quantitative RT-PCR (see Table 1)
and by Western blot, using the rabbit polyclonal antibody that detects only the murine asTF
isoform [9] (kindly provided by Prof. V.Y. Bogdanov, University of Cincinnati College of
Medicine, The Vontz Center for Molecular Studies, Cincinnati, OH, USA), or the murine
flTF-specific antibody [9,15]. To ensure that the effects observed in TF isoform-
overexpressing, stably transfected HL-1 cells were not due to the disruption of the
cardiomyocytic genome, we also utilized transiently transfected cells. Therefore, after the
transfection of cells with TF-isoform-containing plasmids or empty controls, respectively,
the transfected cells were cultured for 48 h in Claycomb medium [25]. Transfected cells
were treated as described below.
2.2. Stimulation of HL-1 cardiomyocytes with TNF-α or Camptothecin (CPT)
TNF-α as well as Camptothecin (CPT) are known to induce apoptosis in several cells, such
as cardiomyocytes [26–28]. TNF-α was demonstrated to induce apoptosis of
cardiomyocytes via caspase-3 activation [26]. CPT binds and stabilizes DNA topoisomerase
I/DNA complexes, leading to DNA breaks and damage. This process results in the activation
of caspase-3 and, subsequently, induction of apoptosis in cardiomyocytes [27,28]. TNF-α-
and CPT-induced apoptosis were shown to be associated with an alteration of the ratio of
pro-apoptotic and anti-apoptotic members of the Bcl-2 family [26,27]. We used TNF-α as
well as CPT to induce experimental apoptosis in cardiomyocytes.
HL-1 sub-lines were grown to confluence and, after serum starvation, cells were treated with
different concentrations of TNF-α (PeproTech) or CPT (Calbiochem) for 16 h or 5 h,
respectively. Protein expression was measured by Western blot analyses using specific
antibodies: anti-TFFL294 (1:1000) and anti-β-actin (1:10000) obtained from Santa Cruz, anti-
active caspase-3 (anti-cleaved caspase-3; 1:500), anti-pErk1/2 (1:1000), anti-pAkt (Ser473;
1:500), anti-Akt (1:1000), anti-NFκB (p65; 1:1000) and anti-p65 (Ser536; 1:1000) obtained
from Cell Signaling Technology, anti-GAPDH (1:10000, Calbiochem) and anti-Bcl-xL
antibody (1:500, BD Pharmingen). Secreted proteins were detected by Western blotting post
precipitation of total proteins from the supernatant by trichloroacetic acid (10 %; Carl Roth
GmbH + Co. KG). mRNA expression levels were determined by semi-quantitative RT-PCR
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(see Table 1). Densities of bands were quantified using Gel-Pro 4 analyzer software (Media
Cybernetics).
2.3. Apoptosis Assay of HL-1 cells
Stimulated and non-stimulated cells were gently harvested and Annexin-V (AV)/propidium
iodide (PI) assay (MoBiTec) was performed according to the manufacturer’s instructions.
The percentages of AV-positive and PI-positive cells were measured by flow cytometry
(FACScan®, Becton Dickinson).
2.4. Inhibition of the Akt/NFκB pathway (integrin-mediated signaling)
HL-1 cells were grown to confluence and serum-starved overnight. Next day, cells were
incubated for 30 min with 2 μM Triciribine (Akt inhibitor [29]) or 10 μM BAY 11-7082
(inhibitor of nuclear factor-kappa B; NFκB), or 100 nM cyclic RGD peptides (cRGD;
inhibitor of integrin-αvβ3), all purchased from Calbiochem, followed by TNF-α stimulation
for 30 min or 16 h (different concentrations) for protein isolation or AV assay.
2.5. Isolation of primary cardiomyocytes and overexpression of asTF
Hearts of C57/BL6 murine embryos (E13.5) were aseptically collected and transferred to 1.5
mL tubes, containing 30 μL ice-cold trypsin/EDTA (0.05%/0.02%; PAA), followed by
digestion at 4°C overnight and then for 15 min at 37°C. After that, 1 mL DMEM (without L-
glutamine, supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, and FBS Gold
10% v/v, PAA) was added to each digested heart. For separation of the different cell types,
cardiac cell suspensions were pooled in a T-75 flask and incubated for 1 h at 37°C to allow
fibroblasts to attach. Afterwards, the supernatant (containing cardiomyocytes) was
transferred to a 12 well-plate (approximately 1.4 hearts/well) pre-coated with fibronectin (5
mg/L in 0.02% (w/v) gelatin, TEBU). 16 h later, cardiomyocytes were adherent and the
medium was changed. After 2 days, the medium was supplemented with BrdU (0.1 mmol/L;
BD Pharmingen). Transfections with the asTF-, flTF-containing or control plasmids were
performed with Lipofectamine2000 according to the manufacturer’s instructions.
Embryonic cardiomyocytes from mice with a cardiomyocyte-specific TF knockout
(TFflox/flox/Mlc2vCre) were isolated as described above. Genotyping of each embryo was
performed as described [6]. All experiments were approved by the Animal Care and Use
Committees of the collaborating institutions in compliance with the National Institute of
Health guidelines.
2.6. Stimulation of embryonic cardiomyocytes with TNF-α
Murine embryonic cardiomyocytes were serum-starved for 2 h followed by TNF-α
stimulation (50 ng/mL) and collected at different time points. For detection of protein
expression, cells were lysed and the lysates were analyzed by Western blot analysis using
anti-active caspase-3 and anti-TFFL294 antibodies. mRNA expression was determined by
quantitative TaqMan®-real time PCR using specific gene expression assays for Bax, Bcl-2,
Bcl-xL, and Akt (Applied Biosystems) normalized against 18S-RNA expression (Applied
Biosystems).
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2.7. Caspase-9 activity assay
Primary embryonic cardiomyocytes were treated with a truncated (“soluble”) form of
recombinant murine flTF (100 nM; (r)sTF, R&D) or recombinant murine asTF (100 nM;
(r)asTF, a generous gift from Prof. V.Y. Bogdanov, University of Cincinnati College of
Medicine, The Vontz Center for Molecular Studies, Cincinnati, OH, USA). The amino acid
composition of murine (r)sTF comprises the entire extracellular domain of murine flTF, and
lacks the transmembrane and the intracellular c-terminal domains. In addition, HL-1 cells,
primary embryonic cardiomyocytes, as well as embryonic TF knockout cardiomyocytes
were transfected transiently with asTF, flTF or empty control plasmids. Thereafter, cells
were incubated with 50 ng/mL of TNF-α. After 16 h, caspase-9 activity was determined by
the caspase-9 colorimetric activity assay kit according to the manufacturer’s protocol
(Millipore). The assay is based on photometric measurement of the chromophore p-
nitroanilide (pNA) at 405 nm using a kinetic ELISA plate reader (Molecular Devices).
2.8. Statistical analyses
All data were expressed as mean ± SEM. Data were analyzed by One-way ANOVA or
Student’s t-test. All probability (p) values ≤ 0.05 were deemed significant.
2.9. Online Supplemental Material
The supplemental text provides details about the generation of asTF-plasmids, Bcl-xL down-
regulation, and immune fluorescence staining.
3. Results
3.1. Overexpression of asTF in HL-1 cells reduces apoptosis
Apoptosis was determined by measuring the percentage of phosphatidlyserine (PS)-positive
cells (AV assay), and PI-positive cells. We generated HL-1 cells overexpressing asTF
(asTF-cells) (Figure 1a). These cells displayed significantly reduced PS exposure and PI-
positivity compared to controls (Figure 1b and c). The apoptosis rate after stimulation with
CPT was also reduced in asTF-overexpressing cardiomyocytic HL-1 cells (asTF cells)
compared to mock transfected control cells (supplemental Figure S2a and b). Next, we
analyzed levels of caspase-3 and 9. Under basal conditions, no active caspase-3 was detected
in asTF-cells or control cells (Figure 1d). TNF-α stimulation induced the generation of
active caspase-3. Compared to asTF-cells, a higher amount of activated caspase-3 was found
in mock-transfected HL-1 cells (Figure 1d). Overexpression of asTF also significantly
reduced caspase-9 activity in TNF-α treated HL-1 cells (Figure 1e). flTF-overexpressing
HL-1 cells (flTF, Figure 1a) also exhibited reduced caspase-9 activity after TNF-α
stimulation compared to stimulated mock transfected cells (Figure 1e).
The impact of pharmacologic inhibitors of the Cdc2-like kinases (Clks) on the TF isoform
expression was characterized on mRNA level (supplemental Figure S2d–f). Treatment of
HL-1 cells with the pharmacologic Clk inhibitors TG003 or KH-CB19, respectively,
reduced the mRNA expression of flTF as well as asTF. The inhibitory effect of the newly
developed Clk inhibitor KH-CB19 was higher than the impact of TG003 at the same
concentration (10 μM), indicating that Clk-dependent activity of spliceosomal factors plays
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an important role in the biosynthesis of flTF and asTF mRNA in murine cardiomyocytes, as
we previously showed to be the case for human flTF and asTF mRNA in endothelial cells
[15].
3.2. Analysis of signal transduction pathways and expression of Bcl-2 proteins
Levels of phosphorylated and non-phosphorylated forms of Akt and Erk1/2 were examined
to evaluate the pathways involved in the asTF-mediated anti-apoptotic effects. Stimulation
with TNF-α led to the activation of Erk1/2 in asTF-cells and control cells, no significant
differences were observed (Figure 2a). Interestingly, both the total expression and the level
of phosphorylated Akt were higher in asTF-cells and remained elevated after stimulation
compared to stimulated control cells (Figure 2b). Akt expression was also induced on the
mRNA level in asTF-cells compared to control cells (Figure 2c). Due to the observed
differences in Akt phosphorylation, we used Triciribine to inhibit Akt phosphorylation. Pre-
treatment of asTF-cells as well as control cells with Triciribine led to a reduction of Akt
phosphorylation in non-stimulated as well as in TNF-α-treated cells (Figure 2d). Triciribine
pre-treatment before TNF-α stimulation abolished the anti-apoptotic effect of asTF (Figure
2e).
Semi-quantitative RT-PCR revealed increased mRNA expression of the pro-survival protein
Bcl-xL in stimulated asTF-overexpressing HL-1 cells, compared to stimulated control cells
(Figure 3a). In contrast, mRNA levels of Bcl-2, Bad, or Bax were not affected (Figure 3a).
The increased Bcl-xL mRNA expression in asTF-cells was associated with increased Bcl-xL
protein levels (Figure 3b). siRNA-mediated knockdown of Bcl-x caused a significant
reduction of Bcl-xL expression, and abolished the pro-survival effect of asTF overexpression
(Figure 3c). Further, Triciribine treatment reduced Bcl-xL mRNA expression in asTF-cells
to levels in mock control cells (Figure 3d). TNF-α stimulation of asTF-cells, flTF-cells, and
mock transfected cells induced mRNA expression of Bcl-xL (Figure 3e). Inhibition of NFκB
with 10 μM BAY 11-7082 reduced the expression of Bcl-xL in non-stimulated and TNF-α-
stimulated cells (Figure 3e). Treatment of HL-1 cells with TNF-α significantly induced
NFκB phosphorylation in asTF-, flTF-, and control cells (Figure 3f). Bcl-xL protein levels
were also indcreased in flTF-cells compared to control cells (supplemental Figure S2c).
Inhibition of integrin-αvβ3 by 100 nM cRGD reduced NFκB phosphorylation in TNF-α-
stimulated asTF-cells, but had no significant impact on flTF-cells or control cells (Figure
3f).
3.3. Reduction of apoptosis in asTF-overexpressing primary cardiomyocytes
Next, we overexpressed asTF and flTF in primary embryonic cardiomyocytes (Figure 4a and
supplemental Figure S1). We observed increased expression of total Akt, phosphorylated
Akt, Bcl-xL, and Bcl-2 in asTF-overexpressing embryonic cardiomyocytes compared to
controls cells (Figure 4b–e). TNF-α treatment resulted in increased caspase-3 activation in
mock transfected cardiomyocytes compared to stimulated asTF-overexpressing embryonic
cardiomyocytes (Figure 4f). Compared to mock controls, transient transfection of embryonic
cardiomyocytes with either asTF- or flTF-expressing plasmids reduced caspase-9 activity 16
h post TNF-α-stimulation (Figure 4g). The observed reduction of caspase-9 activity was
greater in asTF-cells compared to flTF-cells (Figure 4g).
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Because asTF was found to be secreted into the supernatant of asTF-cells (Figure 1a), we
tested the effect of exogenous murine (r)asTF as well as truncated murine flTF – (r)sTF – on
caspase-9 activity in embryonic cardiomyocytes. Compared to controls (wt), treatment of
cardiomyocytes with either (r)asTF or (r)sTF reduced caspase-9 activity 16 h post TNF-α-
induction (Figure 4h). Interestingly, the (r)asTF-treatment after TNF-α stimulation resulted
in a significantly greater reduction of caspase-9 activity compared to (r)sTF-treated
cardiomyocytes (Figure 4h).
3.4. Increased apoptosis in primary TF-deficient cardiomyocytes
To investigate the effect of reduced levels of TF on apoptosis, embryonic cardiomyocytes
were isolated from mice featuring a cardiomyocyte-specific knockout of the TF gene.
Compared to cardiomyocytes with normal TF levels, TF knockout cardiomyocytes exhibited
reduced expression of total Akt, phosphorylated Akt, Bcl-xL, and Bcl-2 (Figure 5a-d). After
stimulation, TF-deficient cardiomyocytes displayed higher levels of activated caspase-3
compared to controls (2.85 ± 0.37 -fold vs. 1.75 ± 0.38-fold, p<0.05; Figure 5e).
Overexpression of either asTF or flTF significantly reduced the activity of caspase-9
compared to mock-transfected controls (Figure 5f). The caspase-9 activity was significant
lower in asTF-cells than in flTF-cells.
4. Discussion
In this study we show that asTF overexpression protects cardiomyocytes against TNF-α- or
CPT-induced apoptosis; these anti-apoptotic effects were mediated by Akt, NFκB, and
integrin-αvβ3 leading to an up-regulation of anti-apoptotic members of the Bcl-2 protein
family. Overexpression of asTF led to a significant reduction of PS exposure and caspase-3
activation in HL-1 cells. Both play central roles in the execution phase of apoptosis [30].
These observations are consistent with the results of other groups showing TNF-α as well as
CPT to induce caspase-3 activation and subsequently apoptosis in several cell types, such as
cardiomyocytes [26–28].
To compare the anti-apoptotic potential of asTF and flTF in cardiomyocytes, we analyzed
the effect of asTF and flTF overexpression on the activation of caspase-9, which plays an
important role in apoptosis of cardiomyocytes [31]. We found that asTF as well as flTF
overexpression reduced caspase-9 activation and TNF-α-induced apoptosis of HL-1 cells.
This is consistent with results of other groups showing that flTF protects cells from
apoptosis [19,20]. In our study, caspase-9 activity was significantly lower in asTF-cells than
in flTF-cells. Similar results were observed using embryonic cardiomyocytes. Vonteo et al.
found that enterovirus cardiac replication – a process known to induce pro-inflammatory
cytokines, such as TNF-α – induces caspase-9 activity and apoptosis in cardiomyocytes
from patients with acute myocarditis [31]. In our experiments, we found TNF-α induced the
activity of caspase-9. In contrast, Bajaj et al. detected no activation of caspase-9 in TNF-α
stimulated HL-1 cells [32]. These discrepancies may be due to differences in the
experimental setting or culture conditions. Moreover, Bajaj et al. used Western blot analyses
to measure caspase-9 expression [32]. Here, we used a quantitative method to determine the
activity of caspase-9 in TNF-α-stimulated HL-1 cells that might be more sensitive to
changes in levels of caspase-9 activation.
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To characterize the role of murine asTF or flTF in the absence of endogenous murine TF
expression, we performed transfection experiments using TF knockout cardiomyocytes [6].
In these experiments, we observed a greater reduction in caspase-9 activity in cells
overexpressing asTF compared with flTF, although we cannot exclude the possibility that
there are different expression levels of the two proteins. Finally, the stimulation of
cardiomyocytes with (r)asTF or (r)sTF also reduced TNF-α-induced caspase-9 activity.
These data suggest that both asTF and flTF exhibit anti-apoptotic activity in murine
cardiomyocytes.
The underlying mechanisms of the asTF and flTF pro-survival effects are unknown. flTF
protects baby kidney hamster cells and human breast cancer cells, but increases apoptosis
via PAR-2 signaling in a keratinocyte cell line [19,20,21]. Erk1/2 [19,33], Akt [20,34], and
NFκB [20] were all found to participate in flTF-associated signaling. In this study, HL-1
cells were found to be protected from apoptosis by asTF and flTF. Erk1/2 phosphorylation
was induced by TNF-α in control cells as well as asTF-cells, suggesting that Erk1/2
activation is not an asTF-associated mediator. Increased expression as well as a persistent
activation of Akt was observed in asTF-cells before and after TNF-α stimulation compared
to control cells. In contrast to asTF-overexpressing cells, mock-transfected control cells
showed an activation of Akt only post stimulation with TNF-α. Activation of Akt improves
cardiomyocyte survival and cardiac remodeling by preventing apoptosis under several
pathological conditions, such as ischemia/reperfusion injury and hypoxia [36] [35] [29,37].
In line with these observations, our study showed that pre-treatment of cells with Triciribine
inhibited the Akt phosphorylation and abolished the asTF-mediated anti-apoptotic effects. In
addition, we found that NFκB inhibition reduced the expression of anti-apoptotic Bcl-xL in
HL-1 cardiomyocytes. These results are consistent with previously reported data showing
that NFκB contributes to anti-apoptotic processes and cell survival [20,38,39].
Recently, asTF was found to mediate pro-angiogenic processes and cell migration via
integrins in human endothelial cells [13]. Furthermore, integrin signaling was shown to
mediate Akt as well as NFκB-dependent cell survival [38,39]. In line with these data, we
found cRGD-mediated inhibition of integrin-αvβ3 to reduce the TNF-α-induced
phosphorylation of NFκB in asTF-cells, but not in control cells or flTF-cells.
Since the Akt pathway impacts mainly the intrinsic apoptosis pathway [40,41], we focused
on this pathway, in which the members of the Bcl-2 protein family are implicated. Members
of the Bcl-2 family are involved in flTF-dependent anti-apoptotic signaling [19,42]. We
demonstrated that Bcl-xL is an important factor in mediating the asTF- and flTF-associated
anti-apoptotic effect in HL-1 cardiomyocytes. Others also demonstrated that TNF-α-induced
apoptosis in cardiomyocytes was associated with an alteration in the ratio of pro-apoptotic
members, such as Bax, and anti-apoptotic members of the Bcl-2 family, such as Bcl-xL [26].
Moreover, Borillo et al. showed recently that overexpression of the Pim-1 kinase, a
downstream effector of Akt-mediated cardio-protection, increased the expression of Bcl-xL
and Bcl-2 in a transgenic mouse model [43]. Together, our data suggest that the TF isoforms
mediate anti-apoptotic effects on HL-1 cardiomyocytic cells via Akt and NFκB; in contrast
to flTF, asTF increased the expression of Bcl-xL through NFκB activation via integrin-αvβ3
signaling.
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Overexpression of asTF in embryonic cardiomyocytes produced anti-apoptotic effects. In
isolated embryonic cardiomyocytes as well as HL-1 cells, TNF-α-induced caspase-3
activation was reduced after transfection with the asTF plasmid compared to mock
transfected cells. Furthermore, we found elevated expression of the anti-apoptotic proteins
Bcl-2 and Bcl-xL in asTF-overexpressing primary cardiomyocytes. It was previously
described that transgenic mice with a heart-specific overexpression of Bcl-2 exhibit a
reduced infarct size and fewer apoptotic cells [44]. Further, Bcl-2 blocks p53-mediated
apoptosis in cardiomyocytes [45] and increases Bcl-xL expression, yielding beneficial
effects by reducing ischemia/reperfusion injury in rat hearts [46]. In isolated embryonic
cardiomyocytes, asTF-overexpression induced the expression of the anti-apoptotic factors
Bcl-2 and Bcl-xL whereas in HL-1 cells, only Bcl-xL expression was elevated as a result of
asTF overexpression. This discrepancy may be due to different developmental stages of the
cell types. Nevertheless, asTF-overexpression resulted in an increased expression of anti-
apoptotic members of the Bcl-2 family in both settings. Our data allows us to postulate that
asTF influences the expression of Bcl-2 proteins.
Reaffirming the association between the asTF level and the survival of the cells,
cardiomyocytes possessing a genetic knockout of the TF gene [47] displayed a higher degree
of TNF-α-induced apoptosis, and decreased activation of the Akt pathway. Moreover, Bcl-2
and Bcl-xL expression was reduced in TF-deficient embryonic cardiomyocytes,
underscoring the positive association between asTF and the Akt pathway on one hand, and
the Bcl-2 protein expression on the other. While the overexpression of asTF as well as flTF
in TF-deficient cardiomyocytes reduced caspase-9 activity, the anti-apoptotic activity of
asTF-transfected cells was higher compared to cells flTF-transfected cells.
The expression of the TF isoforms can be differentially modulated on the post-
transcriptional level by alternative splicing [15, 34]. Regarding the potential physiological
relevance of the induced TF isoform expression under pro-inflammatory conditions, it is
important to note that asTF and flTF can affect different cellular functions, such as
thrombogenicity [15], angiogenesis [13], gene expression [49] or cell survival, as shown in
the present work. In this context, we here report that inhibition of Clks reduces the TF
isoform expression on the mRNA level in resting as well as TNF-α-induced cardiomyocytes
(HL-1 cells). In line with these data, Clks as well as other kinases were demonstrated to
regulate the TF isoform expression in TNF-α-stimulated endothelial cells [15, 34].
Therefore, these data indicate that the Clk kinase family is involved in the modulation of the
differential TF isoform expression in HL-1 cells.
In conclusion, asTF influences the expression of anti-apoptotic Bcl-2 proteins via the Akt
pathway - at least in part - involving NFκB and integrin-αvβ3-mediated signaling processes,
which results in a reduction of the caspase-cascade and subsequent apoptotic cell death in
cardiomyocytes (Figure 6). Therefore, strategies designed to increase myocardial asTF and
flTF expression might be an option to treat heart diseases associated with enhanced
apoptosis of cardiomyocytes. In particular, the minimally coagulant yet highly anti-apoptotic
asTF may comprise a preferred TF isoform whose induction will likely improve heart
muscle function, without a significant risk for thrombotic complications.
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Abbreviations
asTF alternatively spliced TF
AV annexin-V
Bad Bcl-2-Antagonist of Cell Death
Bax Bcl-2-associated X
Bcl-2 B-cell lymphoma 2
Bcl-xL B-cell lymphoma-extra large
CPT Camptothecin
Clk Cdc2-like kinases
cRGD cyclic arginine-glycine-aspartate peptides
DAPI 4′,6-diamidino-2-phenylindole
Erk extracellular-signal regulated kinases
flTF full length TF
FVII/a factor VII/a
FX factor X
GAPDH glyceraldehyde 3-phosphate dehydrogenase
HL-1 murine immortalized cardiomyocytic cell line
MAP kinase mitogen-activated protein kinase
PAR-2 protease-activated receptor 2
PI propidium iodide
PKB/Akt protein kinase B
TF Tissue Factor
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• asTF and flTF protect cardiomyocytes against TNF-α-induced apoptosis.
• asTF exhibits a greater anti-apoptotic potential than flTF.
• The anti-apoptotic effects of asTF are mediated via Akt, NFκB, Integrin-αVβ3
signaling and Bcl-xL expression.
• TF-deficient cardiomyocytes exhibit increased apoptosis compared with wild
type cells.
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Figure 1. Induction of apoptosis in HL-1 cells
a) Stable overexpression of asTF on mRNA level (left) and protein level (middle left, intracellular; middle right, extracellular =
secreted asTF in the supernatant). Right panel shows TF isoform protein expression profile of transiently transfected HL-1 cells.
AV-binding (b) and PI-staining (c) assay comparing stable transfected asTF-cells (grey bars) and mock control cells (white bars)
stimulated with TNF-α for 16 h (n=6). d) Representative Western blot of active (cleaved) caspase-3 in TNF-α-stimulated stably
transfected HL-1 cells post 16 h (1 = controls, 2 and 3: asTF-cells). GAPDH and β-actin were used as loading controls. e)
Caspase-9 activity in TNF-α-stimulated HL-1 cells (n=7–9). Compared are cells transiently overexpressing asTF (grey bars),
flTF (black bars) and mock-transfected controls (white bars). (***) p<0.001, (**) p<0.01, (*) p<0.05.
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Figure 2. Phosphorylation of Erk1/2 and Akt in HL-1 cells and influence of Akt inhibition on apoptosis
Western blots analyses of a) phosphorylated Erk1/2 and b) phosphorylated Akt 30 min post stimulation with TNF-α in stably
transfected cells (controls = white bars; asTF-cells = grey bars; n>6). c) The mRNA expression of total Akt was determined in
stably overexpressing asTF-cells or control cells, respectively (n=4). d) Reduction of Akt phosphorylation by Triciribine in non-
treated or TNF-α-stimulated stably transfected asTF-cells (asTF) or control cells (mock), respectively. e) AV-apoptosis assay of
stably overexpressing cells pre-treated with 2 μM Triciribine and stimulated with TNF-α (n=6). (***) p<0.001; (**) p<0.01; (*)
p<0.05.
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Figure 3. Involvement of Bcl-2 proteins in induced apoptosis in HL-1 cells
Shown is the expression of Bcl-2 family members a) mRNA and b) protein in stably transfected HL-1 cells. a) Compared are
control cells (mock) and asTF-cells (asTF) treated with 50 ng/mL of TNF-α for 2 h. b) Protein expression of Bcl-xL in HL-1
cells (controls and asTF) 6 h post TNF-α stimulation. c) AV-apoptosis assay of stably transfected asTF-cells pre-treated with
siRNAs against Bcl-x (siBcl-x) compared to control cells as well as cells pre-treated with control siRNA (siControl; n=8). d)
Impact of Triciribine on the mRNA expression of Bcl-xL in stably transfected HL-1 cells. e) The Bcl-xL mRNA expression in
transiently transfected TNF-α-induced HL-1 cells pre-treated with an NFκB inhibitor (10 μM; BAY 11-7082) post 2 h (1–4 =
asTF-cells; 5–8 = mock-transfected cells; 9–12 = flTF-cells; “e” empty lanes; n=3). f) Determination of phosphorylated NFκB
(65kDa) in transiently transfected asTF-cells (asTF), flTF-cells (flTF) and control cells (mock) pre-treated with the integrin-
αvβ3 inhibitor (100 nM; cRGD; n=3). Total NFκB (65 kDa) was used as control. (***) p< 0.001; (**) p<0.01; (*) p<0.05.
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Figure 4. Involvement of Bcl-xL, Bcl-2, Akt and activation of caspase-3 and caspase-9 in TNF-α-stimulated embryonic cardiomyocytes
a) Protein expression of the TF isoforms in embryonic cardiomyocytes overexpressing asTF (asTF) or flTF (flTF) compared to
mock-transfected controls. b) Determination of Akt phosphorylation in asTF-overexpressing embryonic cardiomyocytes
compared to controls 0.5 h and 2 h after TNF-α treatment (n=3). Total Akt was also assessed on the protein level in transiently
transfected embryonic cardiomyocytes 30 min post TNF-α stimulation. GAPDH or β-actin were used as loading controls. c-e)
The mRNA expression of c) total Akt and d) Bcl-xL and e) Bcl-2 was assessed 2 h post TNF-α stimulation of asTF-cells or
control cells, respectively (* p<0.05, n=5). f) Shown is the quantification of the relative induction of active caspase-3 expression
and a representative Western Blot (n=4). Embryonic cardiomyocytes transfected with asTF (asTF) or the control plasmid (mock)
were stimulated with 50 ng/mL TNF-α for 0.5 h and 2 h. g, h) Caspase-9 activity in TNF-α-induced embryonic cardiomyocytes
f) transiently transfected with asTF (asTF), flTF (flTF), or empty control vector (mock; n=7–10), and g) cells stimulated with
recombinant asTF ((r)asTF) or the soluble extracellular domain of flTF ((r)sTF; n=4) compared to wild type cells (wt). In f and
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g, the cells were stimulated with TNF-α (50 ng/mL) for 16 h. In all experiments on isolated primary embryonic cardiomyocytes,
transiently transfected cells were used. (***) p<0.001; (**) p<0.01; (*) p<0.05.
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Figure 5. Involvement of Bcl-xL, Bcl-2, Akt and activation of caspase-3 and caspase-9 in stimulated embryonic cardiomyocytes lacking
TF
Shown is (a) Akt mRNA expression, (b) the protein expression and phosphorylation of Akt, (c) Bcl-xL mRNA expression and
(d) Bcl-2 mRNA expression in embryonic TF knockout cardiomyocytes (grey bars, TF−/−-cells) compared to control cells (white
bar; TF+/+-cells) 2 h or 30 min post stimulation with 50 ng/mL TNF-α. e) The increase of active caspase-3 protein of embryonic
TF-deficient cardiomyocytes (grey bar, TF−/−-cells) compared to control cells (white bar; TF+/+-cells) 2 h post stimulation with
50 ng/mL TNF-α (n=4) and a representative Western blots of active caspase-3 and β-actin. f) Caspase-9 activity in embryonic
TF knockout cardiomyocytes transiently transfected with asTF (asTF), flTF (flTF) or the empty control plasmid (mock) after 16
h TNF-α stimulation (n=4–5). (***) p<0.001; (*) p<0.05.
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Figure 6. Signaling pathway underlying the anti-apoptotic effect of asTF and flTF in murine cardiomyocytes
Soluble asTF and membrane-bound flTF induces membrane receptor-mediated signaling. Integrins are possible candidates for
mediating the effects [48], leading - directly or indirectly - to the activation of Akt, which in turn activates NFκB. Activated
NFκB translocates to the nucleus and induces the transcription of its target genes coded within the genomic DNA (gDNA), such
as the anti-apoptotic members of the Bcl-2 family (e.g. Bcl-xL). The induced expression of anti-apoptotic Bcl-2 family members
alters the ratio of anti- and pro-apoptotic factors towards an anti-apoptotic state. This prevents the activation of caspase-3 and
caspase-9 and, finally, reduces TNF-α induced apoptosis, resulting in increased cell survival of cardiomyocytes.
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Table 1
Primer for semi-quantitative PCR
Gene Forward primer (5′ → 3′) Reward primer (5′ → 3′) Tm (°C)
Bax 470bp ATCGAGCAGGGAGGATGGCT CTTCCAGATGGTGAGCGAGG 52





Bad 495bp GAGGAAGTCCGATCCCGGAA CG GCG CTT TGT CGC ATC TGT 52
β-aktin 450bp AGG GAA ATC GTG CGT GAC AT TG TCC ACC TTC CAG CAG ATG 52
flTF: 578bp
asTF: 418bp
CAAGTGCTTCTCGACCACAGACACC AGA TGG TGG CCA GGA GCA 52
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